8-K current report · filed Aug 6, 2026

Relay Therapeutics, Inc. (RLAY) 8-K Current Report: August 6, 2026

Item 1.01Item 2.02Item EX-99.1Item EX-99.2RLAY overview

Short answer

Relay Therapeutics, Inc. (RLAY) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). ATM equity program expanded from $250M to $462.98M, enabling up to $212.98M of additional stock sales.

Relay Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • ATM equity program expanded from $250M to $462.98M, enabling up to $212.98M of additional stock sales
  • Approximately $162.98M already sold under the agreement, indicating substantial prior equity financing
  • Potential dilution and share-price pressure from future issuance, though sales remain discretionary
  • TD Cowen compensation capped at 3.0% of gross proceeds, reducing net cash raised
  • Proceeds provide Relay Therapeutics additional financing flexibility without mandatory borrowing or fixed repayment terms

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full results and management commentary available in Exhibit 99.2
  • Investor focus: cash position, R&D spending, pipeline progress and upcoming catalysts

Item EX-99.1 · Exhibit EX-99.1

  • ATM equity-sales authorization increased from $250 million to $462,978,049, expanding potential financing capacity
  • Additional share issuance creates dilution risk for existing shareholders and possible financing for operations or pipeline development
  • Sales permitted through Nasdaq, block trades, negotiated transactions, or other lawful at-the-market methods
  • Amendment adds outbound-investment compliance representations and updates counsel, address, and General Counsel information
  • Prospectus supplement required within two business days, potentially enabling near-term equity sales visibility

Item EX-99.2 · Exhibit EX-99.2

  • Q2 revenue $0.4M, R&D $76.5M, and net loss $83.7M, reflecting accelerating clinical investment
  • Cash, equivalents and investments $910.9M after $316M gross follow-on proceeds, supporting operations into 2029
  • Zovegalisib triplet produced 44% ORR in heavily pretreated breast cancer patients, supporting frontline development
  • Planned Phase 3 frontline breast cancer trial targeted for early 2027, pending regulatory feedback
  • Vascular-anomaly study showed 60% volumetric response at 12 weeks, with expansion cohorts now open

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Relay Therapeutics, Inc. 8-K filings

Get the next RLAY 8-K as it lands

Follow RLAY for push alerts, or ask the research agent what this filing means.